Skip to main content

Table 3 Parameter estimates (95% confidence intervals) from sensitivity analyses for average HbA1c (mmol/mol) levels over the follow-up

From: Impact of co-payment level increase of antidiabetic medications on glycaemic control: an interrupted time-series study among Finnish patients with type 2 diabetes

 

Baseline level at 01/2015

Pre-policy change trend in 01/2014–12/2016

Change in level at the time of the policy change in 01/2017

Post-policy change trend in 02/2017–9/2019

Primary result

52.40 (51.88 to 52.91)

0.07 (0.04 to 0.09)

0.81 (0.04 to 1.58)

0.03 (− 0.03 to 0.08)

Results from sensitivity analyses when...

 ...excluding 01/2017

52.52 (51.50 to 53.54)

0.06 (0.02 to 0.10)

1.00 (−0.01 to 2.01)

0.03 (−0.07 to 0.13)

 ...excluding 01–02/2017

52.44 (51.89 to 53.00)

0.06 (0.04 to 0.09)

0.72 (−0.13 to 1.57)

0.04 (−0.02 to 0.10)

 ...excluding 01–03/2017

52.81 (51.79 to 53.23)

0.06 (0.03 to 0.10)

0.76 (−0.31 to 1.83)

0.04 (−0.04 to 0.12)

 ...excluding 01–04/2017

52.55 (51.82 to 53.28)

0.06 (0.02 to 0.09)

0.99 (−0.10 to 2.07)

0.04 (−0.05 to 0.12)

 ...excluding 01–05/2017

52.59 (51.53 to 53.66)

0.05 (0.01 to 0.10)

1.28 (0.14 to 2.41)

0.03 (−0.08 to 0.15)

 ...excluding 01–06/2017

52.76 (51.73 to 53.80)

0.04 (0.00 to 0.09)

1.37 (−0.05 to 2.79)

0.04 (−0.09 to 0.16)

 ...applying 2-month time windows

53.04 (52.64 to 53.44)

0.09 (0.05 to 0.12)

0.86 (0.28 to 1.44)

0.06 (−0.01 to 0.12)

 ...restricting the population to those who survived until Oct 1, 2019 (n = 7669)

51.95 (51.46 to 52.45)

0.07 (0.05 to 0.10)

1.00 (0.25 to 1.75)

0.03 (−0.02 to 0.09)